Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • yl01
    Member
    • Aug 2012
    • 25

    #1

    Gene panel exome data

    Hello,

    I have got exome sequencing data from 24 samples. It was done on a MiSeq sequencer. The data are not whole exome data, instead it is gene panel of about 200 genes. I have processed the whole data using the usual whole exome pipeline BWA+GATK, of course with the corresponding bed file. It turned out that the PCR duplication rate in majority of the samples is very high, 70% to 90%. This also caused the mean coverage to be very low, about 4. I am wondering if this is normal in gene panel data. And is it OK in gene panel sequencings to not remove PCR duplicates. Any other points regarding the processing of gene panel exome data is much appreciated.
  • nexgengirl
    Member
    • Apr 2010
    • 31

    #2
    How was the DNA prepared? Was it hybridization or pcr based design? If it was PCR-based you would expect high PCR duplication rate but if it was hybridization based then yes this is high.

    Comment

    • yl01
      Member
      • Aug 2012
      • 25

      #3
      Thank you nexgengirl! I know it was using Agilent HaloPlex technology. So I think it is hybridization based. Right?

      Comment

      • Bukowski
        Senior Member
        • Jan 2010
        • 388

        #4
        Originally posted by yl01 View Post
        Thank you nexgengirl! I know it was using Agilent HaloPlex technology. So I think it is hybridization based. Right?
        Sort of - there's also an amplification step. Read the protocol. You can't deduplicate Halo data, it's not like working with SureSelect. Effectively you get mini-amplicon regions that match up with the restriction digest sites used.

        Comment

        • nexgengirl
          Member
          • Apr 2010
          • 31

          #5
          I have not personally used the Haloplex platform before. I've analyzed a lot of exome data but not Haloplex.

          From briefly looking at the information on the Agilent site it seems that first the DNA is fragmented with restriction enzymes which will be exact cuts (as opposed to "random" shearing in typical exome experiments), second the probes are hybridized (the way its described this also seems very specific since its to the ends of restriction fragments), third the targets are purified and ligated, fourth there is a PCR step, and then fifth sequencing.

          From my interpretation of this setup I would think it would be okay to retain the PCR duplicates (since there's PCR in the 4th step to enrich for your targets) but I would hope someone else who has used the Haloplex technology could comment on this as well.

          Comment

          • nexgengirl
            Member
            • Apr 2010
            • 31

            #6
            See Bukowski answer. It came up as I was entering the previous post.

            Comment

            • yl01
              Member
              • Aug 2012
              • 25

              #7
              Thank you nexgengirl and Bukowski!

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
                by SEQadmin2



                Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

                Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
                ...
                10-14-2026, 09:55 AM
              • SEQadmin2
                New Genomics Technologies Take Aim at Long-Standing Limits
                by SEQadmin2


                Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

                We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
                ...
                09-28-2026, 10:25 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 10-15-2026, 10:52 AM
              0 responses
              25 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-14-2026, 05:39 AM
              0 responses
              31 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-13-2026, 09:56 AM
              0 responses
              27 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-09-2026, 11:14 AM
              0 responses
              28 views
              0 reactions
              Last Post SEQadmin2  
              Working...